StoneRidge PMG Advisors LLC Acquires 2,335 Shares of Elevance Health, Inc. $ELV

StoneRidge PMG Advisors LLC acquired a new stake in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,335 shares of the company’s stock, valued at approximately $908,000.

Several other institutional investors have also modified their holdings of ELV. BlackRock Inc. purchased a new stake in shares of Elevance Health during the second quarter worth about $7,344,424,000. State Street Corp lifted its stake in Elevance Health by 1.3% in the 2nd quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after buying an additional 137,914 shares in the last quarter. Wellington Management Group LLP lifted its stake in Elevance Health by 12.0% in the 2nd quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after buying an additional 984,976 shares in the last quarter. First Eagle Investment Management LLC boosted its holdings in Elevance Health by 1.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock worth $1,619,701,000 after buying an additional 55,905 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Elevance Health in the 2nd quarter worth about $1,246,349,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Activity at Elevance Health

In related news, EVP Ratnakar Lavu sold 1,300 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the completion of the transaction, the executive vice president directly owned 14,849 shares in the company, valued at approximately $6,533,560. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. This trade represents a 34.70% decrease in their position. The SEC filing for this sale provides additional information. 0.34% of the stock is currently owned by insiders.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $29.02 from $27.06, and lifted forecasts for Q1 2027 and Q1 2028 to $11.73 and $12.61, respectively. An additional analyst also raised its Q2 EPS estimate, though the report did not provide the revised figure. Q2 EPS Estimate for Elevance Health Lifted by Analyst
• Neutral Sentiment: EVP Ratnakar Lavu sold 1,300 shares for $572,000, an 8.05% reduction in his holdings. He still directly owned 14,849 shares after the transaction, making the sale a limited insider-sentiment signal. SEC insider transaction filing
• Neutral Sentiment: A separate article considers what would need to be true for Elevance to be an attractive stock purchase, but the supplied article information does not state its conclusion. What Needs To Be True To Buy Elevance Health Stock?
• Negative Sentiment: Zacks Research lowered estimates for Q4 2026 EPS to $2.00 from $2.43, Q3 2027 to $6.01 from $6.70, and Q3 2028 to $7.09 from $7.75. These cuts temper the positive revisions and point to a less favorable outlook for some future quarters.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Royal Bank Of Canada boosted their price objective on Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 22nd. Guggenheim raised their target price on Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Elevance Health in a research note on Thursday, August 13th. Wells Fargo & Company boosted their price target on Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 27th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $451.00 price objective on shares of Elevance Health in a research note on Friday, October 23rd. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus target price of $456.48.

Elevance Health Price Performance

Elevance Health stock opened at $426.17 on Monday. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $412.92 and a 200 day moving average price of $373.58. Elevance Health, Inc. has a 12-month low of $274.84 and a 12-month high of $450.69. The stock has a market cap of $92.08 billion, a P/E ratio of 18.17, a PEG ratio of 2.03 and a beta of 0.63.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. During the same period in the previous year, the business posted $6.03 EPS. Elevance Health’s revenue was up .7% on a year-over-year basis. Sell-side analysts anticipate that Elevance Health, Inc. will post 29.15 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, December 4th. Elevance Health’s payout ratio is presently 29.34%.

Elevance Health Company Profile

Elevance Health, Inc is a U.S. health benefits and services company. Formerly known as Anthem, Inc, it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans.

The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Elevance Health operates primarily in the United States, with health plans serving members across multiple states and access to broader provider networks through its Blue Cross Blue Shield affiliations.